Business Wire

CA-PSMF

2.6.2023 08:16:30 CEST | Business Wire | Press release

Share
10th Annual World Patient Safety, Science & Technology Summit Begins

Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire)

Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospitals. We’re all humans, we’re all a little bit competitive, and I think you react to data. This will make a difference.”

In a keynote address, Don Berwick, MD, MPP, FRCP, former administrator of the Centers for Medicare and Medicaid Services, pointed out that one in four hospital patients experience injury as a result of their care.

“Healthcare is far too unsafe,” said Berwick. “A large proportion of patient safety problems can be eliminated. There are hospitals in this nation that have driven certain kinds of infections to zero and virtually eliminated the risk of pneumonia from ventilation machines.”

Berwick suggested that healthcare systems can learn from many of the safety practices that the aviation industry has successfully put in place. “Today, you would have to fly continuously on a commercial flight for over 6,000 years to have a 50:50 chance of being injured as a passenger,” he said. “Roughly speaking, that means you are more than two million times safer in an airplane seat than in a hospital.”

Jannicke Mellin-Olsen, former president of the World Federation of Societies of Anesthesiologists, used her keynote address to call for more healthcare systems to involve patients and family members of those who have suffered harm in order to help drive better practices. “Involvement means hearing the patient voice at every level of the service,” she said.

The first day of the Summit also featured a talk from Sir Liam Donaldson, former chief medical officer of the United Kingdom, who discussed the impact of Covid-19 on patient safety and how the pandemic illustrated the lack of resilience throughout our healthcare structures. “There wasn’t much thinking about patient safety in the pandemic planning that preceded Covid,” said Donaldson. “Failures to develop world-class infection control facilities put both health workers and patients at risk, but there was also the issue of transitions of care, which greatly affected elderly patients and led to the virus spreading through nursing homes. That should have been part of our thinking from a patient safety perspective.”

Neelam Dhingra, who heads the World Health Organization’s (WHO) Transformative Flagship Initiative, emphasized the need to improve patient safety in low- and middle-income countries. Dhingra pointed out how when WHO conducted a survey of 102 countries in 2022, just 27% had developed a national patient safety action plan, and only 18% had established national targets on reducing medication-related harm.

“In low- and middle-income countries, we are still very far from even simple procedures when it comes to patient safety,” said Dhingra. “Studies from these countries are limited, but the estimates we have suggest that every minute at least five patients die in hospital. This means that the burden of harm in healthcare is grossly underestimated.”

Konrad Reinhart, founding president of the Global Sepsis Alliance, highlighted the continuing need to improve public awareness on sepsis and push for hospitals to comply with best practices. “Given the number of sepsis deaths worldwide, which are higher than cancer, the potential to reduce harm is enormous,” he said.

There were additional talks from world-renowned patient safety champion Peter Pronovost, along with Stephanie Mercado, chief executive officer of the National Association for Healthcare Quality, and Peter Lachman who leads the PSMF’s Fellowship Program. Tedros Adhanom Ghebreyesus, director general of WHO, addressed the Summit in a prerecorded video message.

Panel discussions included contributions from members of the President’s Council of Advisors on Science and Technology regarding their upcoming report on patient safety, as well as an assessment from healthcare leaders on the potential of predictive analytics and AI to improve patient safety.

Other panels touched on subjects ranging from the need for patient and family engagement in healthcare to proposals for forming a National Patient Safety Board. The day’s program ended with a private screening of the HBO documentary Bleed Out.

ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230601006140/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release

The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req

SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release

Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye